Targeting BCL-2 with the BH3 Mimetic ABT-199 in Estrogen Receptor-Positive Breast Cancer

被引：240

作者：

Vaillant, Francois ^{[1
,6
]}

Merino, Delphine ^{[1
,6
]}

Lee, Lily ^{[1
,6
]}

Breslin, Kelsey ^{[1
]}

Pal, Bhupinder ^{[1
,6
]}

Ritchie, Matthew E. ^{[2
,7
]}

Smyth, Gordon K. ^{[3
,7
]}

Christie, Michael ^{[4
,6
,10
]}

Phillipson, Louisa J. ^{[5
,6
]}

Burns, Christopher J. ^{[5
,6
]}

Mann, G. Bruce ^{[8
]}

Visvader, Jane E. ^{[1
,6
]}

Lindeman, Geoffrey J. ^{[1
,9
,11
,12
,13
]}

机构：

[1] Walter & Eliza Hall Inst Med Res, ACRF Stem Cells & Canc Div, Parkville, Vic 3052, Australia

[2] Walter & Eliza Hall Inst Med Res, Mol Med Div, Parkville, Vic 3052, Australia

[3] Walter & Eliza Hall Inst Med Res, Bioinformat Div, Parkville, Vic 3052, Australia

[4] Walter & Eliza Hall Inst Med Res, Syst Biol & Personalised Med Div, Parkville, Vic 3052, Australia

[5] Walter & Eliza Hall Inst Med Res, Chem Biol Div, Parkville, Vic 3052, Australia

[6] Univ Melbourne, Dept Med Biol, Parkville, Vic 3010, Australia

[7] Univ Melbourne, Dept Math & Stat, Parkville, Vic 3010, Australia

[8] Univ Melbourne, Dept Surg, Parkville, Vic 3010, Australia

[9] Univ Melbourne, Dept Med, Parkville, Vic 3010, Australia

[10] Royal Melbourne Hosp, Dept Anat Pathol, Parkville, Vic 3050, Australia

[11] Royal Melbourne Hosp, Dept Med Oncol, Parkville, Vic 3050, Australia

[12] Royal Melbourne Hosp, Breast Serv, Parkville, Vic 3050, Australia

[13] Royal Womens Hosp, Parkville, Vic 3050, Australia

来源：

CANCER CELL | 2013年 / 24卷 / 01期

基金：

澳大利亚国家健康与医学研究理事会; 英国医学研究理事会;

关键词：

CHRONIC LYMPHOCYTIC-LEUKEMIA; SURVIVAL SIGNALS; CELL-DEATH; THERAPY; FAMILY; INHIBITOR; TUMORS; NAVITOCLAX; ABT-737; ACTIVATION;

D O I：

10.1016/j.ccr.2013.06.002

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The prosurvival protein BCL-2 is frequently overexpressed in estrogen receptor (ER)-positive breast cancer. We have generated ER-positive primary breast tumor xenografts that recapitulate the primary tumors and demonstrate that the BH3 mimetic ABT-737 markedly improves tumor response to the antiestrogen tamoxifen. Despite abundant BCL-XL expression, similar efficacy was observed with the BCL-2 selective inhibitor ABT-199, revealing that BCL-2 is a crucial target. Unexpectedly, BH3 mimetics were found to counteract the side effect of tamoxifen-induced endometrial hyperplasia. Moreover, BH3 mimetics synergized with phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) inhibitors in eliciting apoptosis. Importantly, these two classes of inhibitor further enhanced tumor response in combination therapy with tamoxifen. Collectively, our findings provide a rationale for the clinical evaluation of BH3 mimetics in therapy for breast cancer.

引用

页码：120 / 129

页数：10

共 39 条

[21] THE PROLIFERATION OF NORMAL HUMAN BREAST-TISSUE IMPLANTED INTO ATHYMIC NUDE-MICE IS STIMULATED BY ESTROGEN BUT NOT PROGESTERONE [J].

LAIDLAW, IJ ;

CLARKE, RB ;

HOWELL, A ;

OWEN, AWMC ;

POTTEN, CS ;

ANDERSON, E .

ENDOCRINOLOGY, 1995, 136 (01) :164-171

[22] Tamoxifen and ICI 182,780 increase Bcl-2 levels and inhibit growth of breast carcinoma cells by modulating PI3K/AKT, ERK and IGF-1R pathways independent of ERα [J].

Lam, Le ;

Hu, Xiuying ;

Aktary, Zackie ;

Andrews, David W. ;

Pasdar, Manijeh .

BREAST CANCER RESEARCH AND TREATMENT, 2009, 118 (03) :605-621

[23] Patient-derived breast tumor xenografts facilitating personalized cancer therapy [J].

Landis, Melissa D. ;

Lehmann, Brian D. ;

Pietenpol, Jennifer A. ;

Chang, Jenny C. .

BREAST CANCER RESEARCH, 2013, 15 (01)

[24]

Lindeman GJ, 2013, BREAST CANCER MANAG, V2, P1

[25] Programmed anuclear cell death delimits platelet life span [J].

Mason, Kylie D. ;

Carpinelli, Marina R. ;

Fletcher, Jamie I. ;

Collinge, Janelle E. ;

Hilton, Adrienne A. ;

Ellis, Sarah ;

Kelly, Priscilla N. ;

Ekert, Paul G. ;

Metcalf, Donald ;

Roberts, Andrew W. ;

Huang, David C. S. ;

Kile, Benjamin T. .

CELL, 2007, 128 (06) :1173-1186

[26] Bcl-2, Bcl-xL, and Bcl-w are not equivalent targets of ABT-737 and navitoclax (ABT-263) in lymphoid and leukemic cells [J].

Merino, Delphine ;

Khaw, Seong L. ;

Glaser, Stefan P. ;

Anderson, Daniel J. ;

Belmont, Lisa D. ;

Wong, Chihunt ;

Yue, Peng ;

Robati, Mikara ;

Phipson, Belinda ;

Fairlie, Walter D. ;

Lee, Erinna F. ;

Campbell, Kirsteen J. ;

Vandenberg, Cassandra J. ;

Cory, Suzanne ;

Roberts, Andrew W. ;

Ludlam, Mary J. C. ;

Huang, David C. S. ;

Bouillet, Philippe .

BLOOD, 2012, 119 (24) :5807-5816

[27] Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737 [J].

Moore, Victoria Del Gaizo ;

Brown, Jennifer R. ;

Certo, Michael ;

Love, Tara M. ;

Novina, Carl D. ;

Letai, Anthony .

JOURNAL OF CLINICAL INVESTIGATION, 2007, 117 (01) :112-121

[28] Inhibition of PI3K/mTOR Leads to Adaptive Resistance in Matrix-Attached Cancer Cells [J].

Muranen, Taru ;

Selfors, Laura M. ;

Worster, Devin T. ;

Iwanicki, Marcin P. ;

Song, Loling ;

Morales, Fabiana C. ;

Gao, Sizhen ;

Mills, Gordon B. ;

Brugge, Joan S. .

CANCER CELL, 2012, 21 (02) :227-239

[29] Aberrant Expression of Apoptosis-Related Molecules in Endometriosis: A Possible Mechanism Underlying the Pathogenesis of Endometriosis [J].

Nasu, Kaei ;

Nishida, Masakazu ;

Kawano, Yukie ;

Tsuno, Akitoshi ;

Abe, Wakana ;

Yuge, Akitoshi ;

Takai, Noriyuki ;

Narahara, Hisashi .

REPRODUCTIVE SCIENCES, 2011, 18 (03) :206-218

[30] Sensitization of BCL-2-expressing breast tumors to chemotherapy by the BH3 mimetic ABT-737 [J].

Oakes, Samantha R. ;

Vaillant, Francois ;

Lim, Elgene ;

Lee, Lily ;

Breslin, Kelsey ;

Feleppa, Frank ;

Deb, Siddhartha ;

Ritchie, Matthew E. ;

Takano, Elena ;

Ward, Teresa ;

Fox, Stephen B. ;

Generali, Daniele ;

Smyth, Gordon K. ;

Strasser, Andreas ;

Huang, David C. S. ;

Visvader, Jane E. ;

Lindeman, Geoffrey J. .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2012, 109 (08) :2766-2771

← 1 2 3 4 →